Now where was I, oh yeah, coronavirus cultures at the WIV.
The above discussion about recovering viable coronavirus from bat feces is well documented but it's also a useless sidetrack. What matters is that despite Dr Shi claiming they had no viral cultures at the WIV, it was a lie.
We documented the evidence they did indeed have not only SARS-like coronavirus cultures at the WIV, they were doing gain of function research on those cultures. What do you think Shi wanted human adapted mice from Dr Baric for? Shi also learned reverse engineering of coronaviruses from working in Baric's lab. One just needs to look at papers published in 2019 and earlier by Shi and Daszak et al.
And Daszak in his own words in the interview at the Nipah virus conference just before he was aware the pandemic had begun (posted up thread multiple times) said specifically that coronaviruses were easily manipulated in the lab.
PLOS 2017: Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus
Note this was about SARS1 not SARS2. Shi and her colleagues had tracked down the reservoir of SARS1 in horseshoe bats in a cave in Yunnan.
Table
From 2011 - 2015 feces and anal swabs (because that's where the coronaviruses are found) were collected from bat caves in Yunnan, China.
This was not simply the genomes. They cultured the coronaviruses and used serial passages on the cultured virus.
Note they used the SARS backbone. Baric used the HIV backbone.
DNA fragments were inserted... gee, no GoF research here, move along.
[Mel Brooks Frankenstein movie voice]It's alive, it's alive![/]
And so on and so on.
This was at the WIV, not at the lab at the UNC. [post split here to encourage people not to skim it.]
For clarity Rs3367 and RsSHC014 were SARSrCoV identified by PCR and WGS and never cultured, there was no viable virus isolated from fecal sampling. WIV1 and WIV16 are the first and second live viable viruses cultured from bat fecal samples.
https://www.nature.com/articles/nature12711
From your reference
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006698
A total of 602 alimentary specimens (anal swabs or feces) were collected and tested for the presence of CoVs by a Pan-CoV RT-PCR targeting the 440-nt RdRp fragment that is conserved among all known α- and β-CoVs [20]. In total, 84 samples tested positive for CoVs.
...
To understand the genetic diversity of these bat SARSr-CoVs, the most variable region of the SARSr-CoV S gene, corresponding to the receptor-binding domain (RBD) of SARS-CoV, were amplified and sequenced. Due to low viral load in some samples, RBD sequences were successfully amplified only from 49 samples.
....
Based on the diversity of RBD sequences, 11 novel SARSr-CoV strains named by abbreviation of bat species and sample ID (Rs4081, Rs4084, Rs4231, Rs4237, Rs4247, Rs4255, Rs4874, Rs7327, Rs9401, Rf4092 and As6526) were selected for full-length genomic sequencing based on sample abundance, genotype of RBD as well as sampling time.
All thses viruses exist essentially ony as Whole Genome Sequences (WGS) on a database. None of the above viruses were in the form of live viable culturable viruses. But they were trying to isolate live virus and they did so only once, this is the third occasion globally when a live SARS related coronavirus has been isolated from a bat. This is the third of the three isolates in 15 years of trying.
In the current study, we successfully cultured an additional novel SARSr-CoV Rs4874 from a single fecal sample using an optimized protocol and Vero E6 cells [17]. Its S protein shared 99.9% aa sequence identity with that of previously isolated WIV16 and it was identical to WIV16 in RBD.
They then compared the new viable virus with the two previously isolated viable viruses.
To assess whether the three novel SARSr-CoVs can use human ACE2 as a cellular entry receptor, we conducted virus infectivity studies using HeLa cells with or without the expression of human ACE2. All viruses replicated efficiently in the human ACE2-expressing cells. The results were further confirmed by quantification of viral RNA using real-time RT-PCR
This paper does not report gain of function research. It does not utilise recombinant mice. They used the S proteins from the three novel strains on a SARS back bone so that the only variable was the S protein, and the effect of the variations in the S protein could be compared with SARS. This is not gain of function research.
Prior to December 2019 there would habe been no reason not to announce the isolation of viable virus. This paper reports the third viable SARSr CoV to be cultured. None of these three can be turned into SARS-CoV-2 by serial passage or gain of function techniques.

